Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PAION COMPLETES PHASE IIB STUDY WITH SHORT-ACTING ANESTHETIC/SEDATIVE REMIMAZOLAM (CNS 7056) · Phase IIb study completed within 4 months · Headline data expected by end of November · No safety concerns http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/paionp100927en.pdf
InvestorsHub community
Register for free to join our community of investors and share your ideas
You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow